Regulatory

Change in number of shares and votes in SynAct Pharma

During the month of January, the number of shares and votes in SynAct Pharma AB (publ) have increased due to an issue in kind of shares which was resolved upon by the extraordinary general meeting on 12 January 2023.

Through the issue in kind, carried out in January 2023, the number of outstanding shares and votes has increased by 2,172,523, from 29,648,457 to 31,820,980. The share capital has increased by SEK 271,565, from SEK 3,706,057 to SEK 3,977,623.

As of January 31, 2023, the total number of shares and votes in SynAct Pharma AB amounts to 31,820,980 shares and votes.

For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67
Mail: [email protected]              
 
Patrik Renblad
CFO, SynAct Pharma AB 
Phone: +46 707 47 97 68 
Mail: [email protected]

About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com. 

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-01-31 13:00 CET.

Attachments
Change in number of shares and votes in SynAct Pharma

Documents